Chronic eosinophilic pneumonia secondary to levetiracetam
DOI:
https://doi.org/10.32818/reccmi.a7n1a6Keywords:
eosinophilia, levetiracetam, pulmonary eosinophilia, chronic eosinophilic pneumoniaAbstract
Eosinophilic pulmonary diseases constitute a very heterogeneous group of diseases that share clinical manifestations, radiological and/or laboratory findings. Therefore, it is necessary to know the diagnostic criteria for each disease. Chronic idiopathic eosinophilic pneumonia is the most common eosinophilic pneumonia in non-tropical areas where parasitic infections is low. If a clear cause is identified, the most frequent is secondary to drugs and/or toxins.
We present the case of a 21-year-old man diagnosed with chronic eosinophilic pneumonia secondary to treatment with levetiracetam, a generally safe and widely accepted drug in routine clinical practice. A search for the etiology of eosinophilic pulmonary diseases is essential, because identifying a possible cause would allow the withdrawal of the causative agent and to start corticosteroid therapy, so we could prevent the associated morbidity and mortality.
Downloads
Metrics
References
Arnedillo Muñoz A, Hidalgo Molina A. Enfermedades pulmonares eosinofílicas. 2018. Manual Separ Neumología y Cirugía Torácica. Ec-Europe. ISBN 978-84-09-01621-1.
Newsome SD, Xue LY, Jennings T, Castaneda GY. Levetiracetam-Induced Diffuse Interstitial Lung Disease. J Child Neurol. 2007; 22(5): 628-30. https://doi.org/10.1177/0883073807302602.
Cottin V. Eosinophilic Lung Diseases. Clin Chest Med. 2016; 37(3): 535-56. https://doi.org/10.1016/j.ccm.2016.04.015.
Crowe M, Robinson D, Sagar M, Chen L, Ghamande S. Chronic eosinophilic pneumonia: clinical perspectives. Ther Clin Risk Manag. 2019; 15: 397-403. https://doi.org/10.2147/TCRM.S157882.
Valent P, Klion AD, Horny HP, Roufosse F, Gotlib J, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Butterfield JH, Sperr WR, Sotlar K, Vandenberghe P, Haferlach T, Simon HU, Reiter A, Gleich GJ.Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012; 130(3): 607-612.e9. https://doi.org/10.1016/j.jaci.2012.02.019.
Fagan A, Fuld J, Soon E.Levetiracetam-induced eosinophilic pneumonia. BMJ Case Rep. 2017; 2017: bcr2016219121. doi: https://doi.org/10.1136/bcr-2016-219121.
Taweesedt PT, Nordstrom CW, Stoeckel J, Dumic I.Pulmonary Manifestations of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome: A Systematic Review.Biomed Res Int. 2019; 2019: 7863815. doi: https://doi.org/10.1155/2019/7863815.
Dar WR, Sofi N, Latief M, Dar IA, Kasana BA. Levetiracetam induced drug reaction with eosinophilia and systemic symptom syndrome. Indian J Dermatol. 2016; 61(2): 235. doi: https://doi.org/10.4103/0019-5154.177777.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Luis Alberto Pazos-Area, Cristina Ramos-Hernández, Marta Núñez-Fernández, Almudena González-Montaos, José Alberto Fernández-Villar
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
